ELVN — Enliven Therapeutics Income Statement
0.000.00%
- $1.10bn
- $778.74m
- 30
- 26
- 90
- 46
Annual income statement for Enliven Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 24.1 | 41.7 | 51.4 | -0.73 | 83.5 |
Operating Profit | -24.1 | -41.7 | -51.4 | 0.73 | -83.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -23.5 | -41.4 | -51.4 | 1.58 | -71.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.5 | -41.4 | -51.4 | 1.49 | -71.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -23.5 | -41.4 | -51.4 | 1.49 | -71.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.5 | -49.2 | -51.4 | 1.49 | -71.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.66 | -14.1 | -9.49 | -3.2 | -2.01 |
Dividends per Share |